Literature DB >> 17118221

An appraisal of aspirin therapy in diabetes.

John A Colwell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17118221     DOI： 10.1007/s11892-006-0070-3

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  14 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.

Authors:  Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

Review 3.  Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges.

Authors:  Charles H Hennekens; Genell L Knatterud; Marc A Pfeffer
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

4.  Trial of repeated low-dose aspirin in diabetic angiopathy.

Authors:  G DiMinno; M J Silver; A M Cerbone; S Murphy
Journal:  Blood       Date:  1986-10       Impact factor: 22.113

5.  An updated coronary risk profile. A statement for health professionals.

Authors:  K M Anderson; P W Wilson; P M Odell; W B Kannel
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

6.  The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

Authors:  R J Stevens; V Kothari; A I Adler; I M Stratton
Journal:  Clin Sci (Lond)       Date:  2001-12       Impact factor: 6.124

7.  Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.

Authors:  Michael Hayden; Michael Pignone; Christopher Phillips; Cynthia Mulrow
Journal:  Ann Intern Med       Date:  2002-01-15       Impact factor: 25.391

8.  Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.

Authors:  D B Rolka; A Fagot-Campagna; K M Narayan
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

9.  Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors.

Authors:  Barbara V Howard; Lyle G Best; James M Galloway; William James Howard; Kristina Jones; Elisa T Lee; Robert E Ratner; Helaine E Resnick; Richard B Devereux
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

10.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.